-
1
-
-
84975856269
-
Economic costs of diabetes in the U.S. in 2012
-
American Diabetes Association
-
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
-
(2013)
Diabetes Care
, vol.36
, Issue.4
, pp. 1033-1046
-
-
-
2
-
-
84941702063
-
Prevalence of and trends in diabetes among adults in the United States, 1988-2012
-
Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021-1029.
-
(2015)
JAMA
, vol.314
, Issue.10
, pp. 1021-1029
-
-
Menke, A.1
Casagrande, S.2
Geiss, L.3
Cowie, C.C.4
-
3
-
-
84862619470
-
Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective
-
Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol. 2012;57(4):347-370.
-
(2012)
Surv Ophthalmol
, vol.57
, Issue.4
, pp. 347-370
-
-
Sivaprasad, S.1
Gupta, B.2
Crosby-Nwaobi, R.3
Evans, J.4
-
4
-
-
77953555650
-
Burden of illness of diabetic macular edema: Literature review
-
Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7):1587-1597.
-
(2010)
Curr Med Res Opin
, vol.26
, Issue.7
, pp. 1587-1597
-
-
Chen, E.1
Looman, M.2
Laouri, M.3
-
5
-
-
84863320414
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
-
(2012)
Ophthalmology
, vol.119
, Issue.7
, pp. 1388-1398
-
-
Martin, D.F.1
Maguire, M.G.2
-
6
-
-
84886430519
-
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-Year findings of the IVAN randomised controlled trial
-
Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
-
(2013)
Lancet
, vol.382
, Issue.9900
, pp. 1258-1267
-
-
Chakravarthy, U.1
Harding, S.P.2
Rogers, C.A.3
-
7
-
-
84891631034
-
Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies
-
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
-
(2014)
Ophthalmology
, vol.121
, Issue.1
, pp. 193-201
-
-
Schmidt-Erfurth, U.1
Kaiser, P.K.2
Korobelnik, J.F.3
-
8
-
-
84925423332
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network
-
Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
-
(2015)
N Engl J Med
, vol.372
, Issue.13
, pp. 1193-1203
-
-
Wells, J.A.1
Glassman, A.R.2
-
9
-
-
84975698767
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial
-
Epub ahead of print
-
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; [Epub ahead of print]. doi: 10.1016/j.ophtha.2016.02.022.
-
(2016)
Ophthalmology
-
-
Wells, J.A.1
Glassman, A.R.2
Ayala, A.R.3
-
10
-
-
84941287133
-
Comparative effectiveness trial for diabetic macular edema: Three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network
-
Jampol LM, Glassman AR, Bressler NM. Comparative effectiveness trial for diabetic macular edema: three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015;133(9):983-984.
-
(2015)
JAMA Ophthalmol
, vol.133
, Issue.9
, pp. 983-984
-
-
Jampol, L.M.1
Glassman, A.R.2
Bressler, N.M.3
-
12
-
-
84870723704
-
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
-
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
-
(2012)
Ophthalmology
, vol.119
, Issue.12
, pp. 2537-2548
-
-
Heier, J.S.1
Brown, D.M.2
Chong, V.3
-
13
-
-
77949352911
-
Prospective evaluation of visual acuity assessment: A comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis)
-
Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009;107:311-324.
-
(2009)
Trans Am Ophthalmol Soc
, vol.107
, pp. 311-324
-
-
Kaiser, P.K.1
-
14
-
-
84862847569
-
Time to first treatment: The significance of early treatment of exudative age-related macular degeneration
-
Rauch R, Weingessel B, Maca SM, et al. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina. 2012;32(7):1260-1264.
-
(2012)
Retina
, vol.32
, Issue.7
, pp. 1260-1264
-
-
Rauch, R.1
Weingessel, B.2
Maca, S.M.3
-
15
-
-
84872072339
-
Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
-
Brown DM, Tuomi L, Shapiro H, Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013;33(1):23-34.
-
(2013)
Retina
, vol.33
, Issue.1
, pp. 23-34
-
-
Brown, D.M.1
Tuomi, L.2
Shapiro, H.3
-
16
-
-
79958843614
-
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study
-
Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049.
-
(2011)
Ophthalmology
, vol.118
, Issue.10
, pp. 2041-2049
-
-
Campochiaro, P.A.1
Brown, D.M.2
Awh, C.C.3
-
17
-
-
84885022258
-
Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE
-
Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
-
(2013)
Ophthalmology
, vol.120
, Issue.10
, pp. 2013-2022
-
-
Brown, D.M.1
Nguyen, Q.D.2
Marcus, D.M.3
-
18
-
-
84911381185
-
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
-
Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;9:CD011230.
-
(2014)
Cochrane Database Syst Rev
, vol.9
-
-
Moja, L.1
Lucenteforte, E.2
Kwag, K.H.3
-
19
-
-
84958568980
-
Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis
-
Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21-29.
-
(2016)
JAMA Ophthalmol
, vol.134
, Issue.1
, pp. 21-29
-
-
Avery, R.L.1
Gordon, G.M.2
-
20
-
-
84961924620
-
Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
-
Avery RL. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). Ophthalmology. 2016;123(2):e14-16.
-
(2016)
Ophthalmology
, vol.123
, Issue.2
, pp. e14-e16
-
-
Avery, R.L.1
-
21
-
-
84959361928
-
Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration
-
Etminan M, Maberley DA, Babiuk DW, Carleton BC. Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016;163:53-58.
-
(2016)
Am J Ophthalmol
, vol.163
, pp. 53-58
-
-
Etminan, M.1
Maberley, D.A.2
Babiuk, D.W.3
Carleton, B.C.4
-
22
-
-
84908354473
-
Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
-
Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611-1621.
-
(2014)
Clin Ophthalmol
, vol.8
, pp. 1611-1621
-
-
Kiss, S.1
Liu, Y.2
Brown, J.3
-
23
-
-
84908118639
-
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
-
Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
-
(2014)
Ophthalmology
, vol.121
, Issue.10
, pp. 1904-1914
-
-
Boyer, D.S.1
Yoon, Y.H.2
Belfort, R.3
-
24
-
-
84867099927
-
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
-
Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
-
(2012)
Ophthalmology
, vol.119
, Issue.10
, pp. 2125-2132
-
-
Campochiaro, P.A.1
Brown, D.M.2
Pearson, A.3
-
26
-
-
84920971127
-
Evaluation of compounded bevacizumab prepared for intravitreal injection
-
Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015;133(1):32-39.
-
(2015)
JAMA Ophthalmol
, vol.133
, Issue.1
, pp. 32-39
-
-
Yannuzzi, N.A.1
Klufas, M.A.2
Quach, L.3
-
27
-
-
84879798373
-
Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: One-year outcomes and investigative results
-
Goldberg RA, Flynn HW Jr., Miller D, Gonzalez S, Isom RF. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology. 2013;120(7):1448-1453.
-
(2013)
Ophthalmology
, vol.120
, Issue.7
, pp. 1448-1453
-
-
Goldberg, R.A.1
Flynn, H.W.2
Miller, D.3
Gonzalez, S.4
Isom, R.F.5
-
28
-
-
84983761869
-
Cost effectiveness of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
-
February 24-27, Miami, FL
-
Jampol LM, Risse E, Hutton D, et al. Cost effectiveness of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Paper presented at: Macula Society Annual Meeting; February 24-27, 2016; Miami, FL.
-
(2016)
Macula Society Annual Meeting
-
-
Jampol, L.M.1
Risse, E.2
Hutton, D.3
|